메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 27, Issue 27, 2009, Pages
Trastuzumab beyond disease progression: Case closed?
Author keywords

[No Author keywords available]
Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;
EID: 74549197481     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.8873     Document Type: Letter
Times cited : (6)
References (11)
  • 1
    • 65349110371 scopus 로고    scopus 로고
    • Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study
    • von Minckwitz G, du Bois A, Schimdt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27:1999-2006, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 1999-2006
    • von Minckwitz, G.1    du Bois, A.2    Schimdt, M.3
  • 2
    • 34447314315 scopus 로고    scopus 로고
    • registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer
    • suppl; abstr 670, 46s
    • Tanchiu E, Kaufman PA, Paik S, et al: registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer. J Clin Oncol 23:46s, 2005 (suppl; abstr 670)
    • (2005) J Clin Oncol , vol.23
    • Tanchiu, E.1    Kaufman, P.A.2    Paik, S.3
  • 3
    • 1842614245 scopus 로고    scopus 로고
    • Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression
    • Tripathy D, Slamon DJ, Cobleigh M, et al: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22:1063-1070, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 1063-1070
    • Tripathy, D.1    Slamon, D.J.2    Cobleigh, M.3
  • 4
    • 0041696794 scopus 로고    scopus 로고
    • Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group
    • Fountzilas G, Razis E, Tsavdaridis D, et al: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 4:120-125, 2003
    • (2003) Clin Breast Cancer , vol.4 , pp. 120-125
    • Fountzilas, G.1    Razis, E.2    Tsavdaridis, D.3
  • 5
    • 3042676349 scopus 로고    scopus 로고
    • Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories
    • Gelmon KA, Mackey J, Verma S, et al: Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 5:52-58, 2004
    • (2004) Clin Breast Cancer , vol.5 , pp. 52-58
    • Gelmon, K.A.1    Mackey, J.2    Verma, S.3
  • 6
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
    • (2006) N Engl J Med , vol.355 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3
  • 7
    • 2942659576 scopus 로고    scopus 로고
    • Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
    • Pegram MD, Konecny GE, O'Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004
    • (2004) J Natl Cancer Inst , vol.96 , pp. 739-749
    • Pegram, M.D.1    Konecny, G.E.2    O'Callaghan, C.3
  • 8
    • 66249091930 scopus 로고    scopus 로고
    • The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine
    • Ross JS, Slodkowska EA, Symmans WF, et al: The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320-368, 2009
    • (2009) Oncologist , vol.14 , pp. 320-368
    • Ross, J.S.1    Slodkowska, E.A.2    Symmans, W.F.3
  • 9
    • 34447306848 scopus 로고    scopus 로고
    • Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
    • Valabrega G, Montemurro F, Aglietta M: Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18:977-984, 2007
    • (2007) Ann Oncol , vol.18 , pp. 977-984
    • Valabrega, G.1    Montemurro, F.2    Aglietta, M.3
  • 10
    • 5144226211 scopus 로고    scopus 로고
    • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    • Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004
    • (2004) Cancer Cell , vol.6 , pp. 117-127
    • Nagata, Y.1    Lan, K.H.2    Zhou, X.3
  • 11
    • 34247588567 scopus 로고    scopus 로고
    • Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
    • Scaltriti M, Rojo F, Ocana A, et al: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638, 2007
    • (2007) J Natl Cancer Inst , vol.99 , pp. 628-638
    • Scaltriti, M.1    Rojo, F.2    Ocana, A.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.